Oncology Prostate and Urologic Cancers Prostate Metastatic Castrate Resistant Aggressive Variant
Categories
Protocols
HCRN-GU23-655-NAPOLEON Phase II OPEN TO ACCRUAL
Phase II Study of Zanzalintinib in Men with Aggressive Variant Prostate Cancer (NAPOLEON study)